Stockscreener 앱 받기
28.18
0.32%
-0.09
시간 외 거래:
28.18
전일 마감가:
$28.27
열려 있는:
$28.44
하루 거래량:
1.48M
Relative Volume:
0.72
시가총액:
$2.60B
수익:
$333.87M
순이익/손실:
$-169.00M
주가수익비율:
-13.81
EPS:
-2.04
순현금흐름:
$-157.30M
1주 성능:
-3.95%
1개월 성능:
-11.05%
6개월 성능:
+33.24%
1년 성능:
+43.05%
1일 변동 폭
$27.85
$28.59
1주일 범위
$27.85
$30.15
52주 변동 폭
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
28.18 | 2.61B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재개 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-21 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Vanguard Group Inc. Has $158.06 Million Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Exploring a 44.65% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Legato Capital Management LLC Acquires Shares of 71,030 Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
TVTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Total debt per share of Travere Therapeutics, Inc. – BOATS:TVTX - TradingView
Travere Therapeutics (TVTX) Is Up 7.4% After FILSPARI-Fueled Revenue Surge And Narrower LossesHas The Bull Case Changed? - simplywall.st
Travere Therapeutics, Inc. (TVTX) Stock Analysis: A 39% Upside Potential Sparks Investor Interest - DirectorsTalk Interviews
Travere Therapeutics (TVTX) CEO sells 60,000 shares in 10b5-1 trade - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory - Finviz
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 - Finviz
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms (NASDAQ:TVTX) - Seeking Alpha
A Look At Travere Therapeutics (TVTX) Valuation After Q4 Earnings Beat And FILSPARI Regulatory Progress - Yahoo Finance
Assessing Travere Therapeutics (TVTX) Valuation After Strong Earnings Beat And Pipeline Progress - Sahm
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to Buy - MarketBeat
Travere outlines FILSPARI-driven growth and new FSGS milestone as 2026 begins - MSN
Travere Therapeutics Earnings Call Shows Growth Amid Risks - TipRanks
TVTX (NASDAQ): Affiliate files Form 144 to sell 60,000 shares - Stock Titan
How liquid is Travere Therapeutics Inc. stockJuly 2025 Volume & Daily Chart Pattern Signals - mfd.ru
Travere Therapeutics (NASDAQ:TVTX) Shares Down 5.4%Should You Sell? - MarketBeat
Travere Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Highlights - GuruFocus
Decoding Travere Therapeutics Inc (TVTX): A Strategic SWOT Insig - GuruFocus
Travere Therapeutics Q4 Earnings Call Highlights - MarketBeat
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
TVTX: FILSPARI drove record revenue and patient growth in 2025, with strong outlook for 2026 - TradingView
Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates - Yahoo Finance
Travere Therapeutics, Inc. SEC 10-K Report - TradingView
TVTX: 2025 revenue surged to $490.7M on FILSPARI growth; net loss narrowed and pipeline advanced - TradingView
Travere Therapeutics (NASDAQ:TVTX) Announces Quarterly Earnings Results, Beats Estimates By $0.42 EPS - MarketBeat
Travere Therapeutics posts surprise Q4 profit; Shares slip 5% on revenue miss - Investing.com Canada
Travere: Fourth Quarter Financial Results Overview - Bitget
Travere: Q4 Earnings Snapshot - KVUE
Earnings Flash (TVTX) Travere Therapeutics, Inc. Posts Q4 Adjusted EPS $0.37 per Share, vs. FactSet Est of $0.38 - marketscreener.com
FILSPARI surge drives Travere Therapeutics (TVTX) to 2025 non-GAAP profit - Stock Titan
Travere Therapeutics Q4 Earnings Report: What Investors Need to Know - Benzinga
Travere Therapeutics faces earnings test amid FSGS approval delay By Investing.com - Investing.com UK
Travere Therapeutics faces earnings test amid FSGS approval delay - Investing.com Australia
Stocks with rising relative price strength: Travere Therapeutics - MSN
Earnings Outlook For Travere Therapeutics - Benzinga
Aberdeen Group plc Acquires 70,791 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market - Finviz
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? - AOL.com
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Unpacking A 52.25% Potential Upside - DirectorsTalk Interviews
How New Filspari Reviews And Price Targets Are Rewriting The Story For Travere Therapeutics (TVTX) - Yahoo Finance
Is Travere Therapeutics (TVTX) Still Attractive After Recent Share Price Volatility? - Yahoo Finance
Precision Trading with Travere Therapeutics Inc. (TVTX) Risk Zones - Stock Traders Daily
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):